Cancer Treatment News and Research

RSS

University of Copenhagen professors receive 2012 Carlsberg Foundations Research Prize

The Carlsberg Foundations Research Prizes 2012 goes to Professor in molecular biology Kristian Helin and Professor in international politics Ole W-ver. Each researcher receives 1 million DKK where - should be spend on further research.

24 Sep 2012

UC San Diego’s bold plan aims to personalize cancer treatment

UC San Diego Moores Cancer Center launched a bold plan today aimed at personalizing cancer treatment. The "My Answer to Cancer" team of oncologists, bioinformaticians, pathologists and geneticists pledges to "sequence" or analyze the DNA of large numbers of patients with cancer in order to match each patient to the best available drug for his or her particular tumor.

19 Sep 2012

Abiraterone acetate confirmed to offer significant survival benefit to advanced prostate cancer patients

Results of a phase 3 trial published in The Lancet Oncology have confirmed that the drug abiraterone acetate (marketed as Zytiga®) offers a significant survival benefit to patients with castration-resistant prostate cancer, which is spreading to other parts of their body (known as metastatic prostate cancer).

18 Sep 2012

CINJ experts available to discuss prevention and treatment of breast cancer

The Cancer Institute of New Jersey (CINJ) is making experts available to discuss the risks, and options for treatment and prevention surrounding breast cancer. According to the American Cancer Society 227,000 women nationwide will be diagnosed with the disease this year, and while the disease affects mostly women, men also can be diagnosed with breast cancer.

15 Sep 2012

Scientists describe how DNA origami can enhance effect of cytostatics in cancer treatment

Scientists at Karolinska Institutet in Sweden describe in a new study how so-called DNA origami can enhance the effect of certain cytostatics used in the treatment of cancer. With the aid of modern nanotechnology, scientists can target drugs direct to the tumour while leaving surrounding healthy tissue untouched.

14 Sep 2012

Solubilized curcumin shrinks lung tumors in mice

Belgian researchers report that orally administered curcumin can reduce the size of lung cancer tumors in mice.

13 Sep 2012

Changes in physical characteristics of regulatory T cell can predict MDS progression risk

Researchers at Moffitt Cancer Center and colleagues have discovered that changes in the physical characteristics of the effector memory regulatory T cell can predict the progression risk of myelodysplastic syndromes (MDS) to acute myeloid leukemia. The finding could improve prognostication for patients with MDS and better inform therapeutic decision making.

13 Sep 2012

Blood pressure, oxygen saturation predict death in terminally ill

The most reliable events that predict impending death in terminally ill cancer patients being treated palliatively are decreased blood pressure and low oxygen saturation, show study results.

12 Sep 2012

MD Anderson joins API’s Actimab-A Phase I/II trial in acute myeloid leukemia

Actinium Pharmaceuticals, Inc. (API), a biopharmaceutical company that develops innovative targeted payload immunotherapeutics, announced that MD Anderson Cancer Center in Houston, Texas has joined the Company's ongoing Phase I/II trial in newly diagnosed patients with acute myeloid leukemia (AML).

12 Sep 2012

U.S. to cover costs of cancer monitoring, treatment for 9/11 first responders

The 70,000 surviving firefighters, police officers and other first responders who raced to the World Trade Center after the attacks of September 11, 2001 will be entitled to free monitoring and treatment for some 50 forms of cancer.

12 Sep 2012

Berkeley lab researchers link possible new oncogene with resistance to cancer drugs

A gene that may possibly belong to an entire new family of oncogenes has been linked by researchers with the U.S. Department of Energy (DOE)'s Lawrence Berkeley National Laboratory (Berkeley Lab) to the resistance of breast cancer to a well-regarded and widely used cancer therapy.

12 Sep 2012

Adding bavituximab to docetaxel doubles overall survival in late-stage NS-NSCLC patients

Adding the monoclonal antibody bavituximab to docetaxel chemotherapy doubles overall response rate and improves progression-free survival and overall survival in late-stage non-squamous, non-small cell lung cancer (NS-NSCLC) patients who have already received one prior chemotherapy regimen, according to research presented at the 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology.

7 Sep 2012

PCI after lung cancer treatment reduces risk of brain metastases in stage III NSCLC patients

Stage III non-small cell lung cancer (NSCLC) patients treated with surgery and/or radiation therapy have a significantly reduced risk of developing brain metastases if they also receive prophylactic cranial irradiation (PCI); however, this study did not show an improvement in overall survival with PCI, according to research presented at the 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology.

7 Sep 2012

Researchers identify HIF2α gene mutation in cancer tumor cells

For the first time, a mutation in HIF2α, a specific group of genes known as transcription factors that is involved in red blood cell production and cell metabolism, has been identified in cancer tumor cells.

6 Sep 2012

Pediatric central line infections reduced by ‘best practice’ guidelines

The number of central line-associated bloodstream infections sustained by hospitalized children with cancer can be substantially reduced by encouraging staff to follow simple “best practice” regulations, say researchers.

4 Sep 2012

Triple-threat approach can reduce invasive bloodstream infections in pediatric cancer patients

Hospitals can dramatically reduce the number of life-threatening central line infections in pediatric cancer patients by following a set of basic precautions, by encouraging families to speak up when they observe noncompliance with the protocol and by honest analysis of the root cause behind every single infection, according to a new Johns Hopkins Children's Center study.

3 Sep 2012

Astellas Pharma receives FDA approval for Xtandi to treat metastatic CRPC

The U.S. Food and Drug Administration today approved Xtandi (enzalutamide) to treat men with late-stage (metastatic) castration-resistant prostate cancer that has spread or recurred, even with medical or surgical therapy to minimize testosterone.

1 Sep 2012

Study explains why some cancer vaccines are not as effective as hoped

A research report published in the September 2012 issue of the Journal of Leukocyte Biology offers a possible explanation of why some cancer vaccines are not as effective as hoped, while at the same time identifies a new therapeutic strategy for treating autoimmune problems. In the report, scientists suggest that cancer, even in the very early stages, produces a negative immune response from dendritic cells, which prevent lymphocytes from working against the disease.

31 Aug 2012

Weill Cornell Medical College receives three new research grants for translational blood cancer study

Weill Cornell Medical College has been awarded three new research grants from the Leukemia & Lymphoma Society totaling $1.8 million. The funds will support critically-needed translational research for blood cancers, accelerating promising discoveries from the laboratory to the patient's bedside.

31 Aug 2012

Studies examine how PML gene regulates the fatty acid oxidation pathway

Two papers led by scientific teams from the Cancer Genetics Program at Beth Israel Deaconess Medical Center (BIDMC) shed new light on the genetic mechanisms underlying cellular energy and metabolism and, at the same time, highlight both the challenges and opportunities of genetic approaches to cancer treatment.

31 Aug 2012

Cancer Treatment News and Research

University of Copenhagen professors receive 2012 Carlsberg Foundations Research Prize

UC San Diego’s bold plan aims to personalize cancer treatment

Abiraterone acetate confirmed to offer significant survival benefit to advanced prostate cancer patients

CINJ experts available to discuss prevention and treatment of breast cancer

Scientists describe how DNA origami can enhance effect of cytostatics in cancer treatment

Solubilized curcumin shrinks lung tumors in mice

Changes in physical characteristics of regulatory T cell can predict MDS progression risk

Blood pressure, oxygen saturation predict death in terminally ill

MD Anderson joins API’s Actimab-A Phase I/II trial in acute myeloid leukemia

U.S. to cover costs of cancer monitoring, treatment for 9/11 first responders

Berkeley lab researchers link possible new oncogene with resistance to cancer drugs

Adding bavituximab to docetaxel doubles overall survival in late-stage NS-NSCLC patients

PCI after lung cancer treatment reduces risk of brain metastases in stage III NSCLC patients

Researchers identify HIF2α gene mutation in cancer tumor cells

Pediatric central line infections reduced by ‘best practice’ guidelines

Triple-threat approach can reduce invasive bloodstream infections in pediatric cancer patients

Astellas Pharma receives FDA approval for Xtandi to treat metastatic CRPC

Study explains why some cancer vaccines are not as effective as hoped

Weill Cornell Medical College receives three new research grants for translational blood cancer study

Studies examine how PML gene regulates the fatty acid oxidation pathway

Cancer Research eBook

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News